A kind of gene therapy recombinant vector mediated by plasmid vector

Abstract

The invention discloses plasmid vector mediated gene therapy recombinant vectors of the same category. The invention relates to the field of bio-pharmaceuticals and particularly relates to a recombinant vector capable of efficiently expressing a human hepatocyte growth factor and the application thereof. The invention further relates to the application of a medicine containing a constructed enhanced signal peptide for improving protein expression and a composition thereof in preparation of medicines for treating lower extremital arterial ischemic disease.

Description

technical field [0001] The invention belongs to the field of biopharmaceuticals, and in particular relates to a recombinant vector capable of highly expressing human hepatocyte growth factor and its application. Background technique [0002] Ischemic diseases, especially arterial ischemic diseases, mainly include coronary heart disease and limb arteriosclerotic obliterans, the main cause of which is arteriosclerosis. Arteriosclerosis leads to the deposition of fat and cholesterol on the inner wall of blood vessels, accompanied by pathological changes such as fibrosis and calcification, which gradually leads to stenosis of blood vessel lumen, insufficient blood supply, and arterial ischemic diseases. According to the World Health Organization, 17 million people die from heart disease and other cardiovascular diseases every year, accounting for about one-third of the global death toll. The morbidity and mortality are increasing year by year. It will probably exceed 20 million...

AI Technical Summary

Problems solved by technology

[0011] 1. The intron sequence used is relatively large, and the non-structural gene sequence introduced into the promoter is too large in order to increase the expression rate, resulting in a large entire plasmid, which is about 7.4kb. Therefore, it can be transfected without the help of external force Eukaryotic cells are less efficient;

[0012] 2. Because the recombinant plasmid is too large, the transfection rate is low, and the expression efficiency in the body is low, resulting in a relatively high dose (8-16 mg / time) for clinical needs. On the one hand, it leads to high production costs, high drug costs for patients, and heavy burden; on the other hand On the one hand, high-dose medication introduces more impurities, which may lead to increased toxic and side effects, thereby increasing clinical risks

[0013] 3. The expression ratio of the two isoforms is uncontrollable due to the difference in the cutting mechanism in different cells

Images